TMDX
TransMedics Group, Inc.
NASDAQ · Healthcare · Medical - Devices · US
$86.42
−0.28%Price chart
Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18
Key dataSep 18, 2026
Open$87.28
From 52W high−42.55%
Volume1.44M
Market cap$3.00B
P/E (TTM)19.6x
P/S (TTM)4.5x
Div yield—
Key dataSep 18, 2026
Open
$87.28
From 52W high
−42.55%
Volume
1.44M
Market cap
$3.00B
ValuationView details →
P/E (Fwd)
46.5x
EV/EBITDA
28.3x
P/E (TTM)
19.6x
RSI (14)
52.6
MomentumView details →
1D Return
−0.28%
YTD Return
−27.94%
SummaryUpdated Jun 1, 2026
TransMedics Group, Inc. (NASDAQ:TMDX) is a commercial-stage medical technology company founded in 1998 and headquartered in Andover, Massachusetts. The company has transformed from a research-focused startup into a leading provider of organ preservation technology for transplant procedures. TransMedics went public in May 2019 and has since established itself as a key player in the organ transplantation market, operating primarily in the United States with expanding international presence. The company has experienced rapid growth, particularly following the launch of its National OCS Program (NOP) which provides comprehensive transplant logistics services.
Similar companies
Latest newsMore news →
TransMedics Group, Inc. appointed Fernando Araujo as Chief Financial Officer and Treasurer, effective September 21, 2026.10d agoEmerald Investment Advisers LLC acquired a new stake of 30,456 shares in TransMedics Group, Inc. during the quarter, valued at approximately $2,023,000, as disclosed to the SEC.28d ago